Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegnivacogin + anivamersen
- Development stage
- Discontinued
- Lead developer
- Allergan
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
**Pegnivacogin + anivamersen** is an investigational, actively controllable anticoagulation system developed for anticoagulation during percutaneous coronary intervention in acute coronary syndrome and coronary artery disease. Pegnivacogin is a PEGylated 31-nucleotide single-stranded RNA aptamer that directly and selectively inhibits activated coagulation factor IX, while anivamersen is a complementary 15-nucleotide oligonucleotide reversal agent that binds pegnivacogin through Watson-Crick base pairing and neutralizes its anticoagulant activity. Development of the REG1 system, later branded Revolixys Kit, was terminated after severe immediate allergic reactions associated with pre-existing anti-PEG antibodies occurred during clinical development. ([thelancet.com](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2900515-2/fulltext))
- Brand names
- RevolixysRevolixys Kit
- Other names
- pegnivacogin/anivamersenREG1 anticoagulation systemREG-1 anticoagulation systemREG 1 anticoagulation systemRB006 + RB007
02
Targets
Coagulation Factor IXa
Beyond the preview
Go deeper on pegnivacogin + anivamersen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegnivacogin + anivamersen.